Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022
2022年3月7日 - 10:30PM
ビジネスワイヤ(英語)
Company conference call and webcast at 4:30 PM
EDT
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a
commercial-stage, cancer prevention medical diagnostics company, a
majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ),
today announced that the companies will host a business update
conference call on Monday, March 28, 2022, at 4:30 PM EDT. During
the call, Lishan Aklog, M.D., Chairman, and Chief Executive
Officer, will provide a business update including an overview of
the Company’s near-term milestones and growth strategy. In
addition, Dennis McGrath, Lucid’s Chief Financial Officer, will
discuss the companies’ fourth quarter 2021 financial results.
To access the conference call, U.S.-based listeners should dial
877-407-0789 and international listeners should dial 201-689-8562.
All listeners should provide the operator with the conference call
name “Lucid Business Update Conference Call” to join. Individuals
interested in listening to the live conference call via the webcast
may do so by visiting the investor relations section of the
Company’s website at www.luciddx.com.
Following the conclusion of the conference call, a replay will
be available for one week and can be accessed by dialing
844-512-2921 from within the U.S. or 412-317-6671 from outside the
U.S. To access the replay, all listeners should provide the
following pin number: 13727145. The webcast will be available for
replay on the investor relations section of the Company’s website
at www.luciddx.com.
About Lucid
Lucid Diagnostics Inc is a commercial-stage, cancer prevention
medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is
focused on the millions of patients with gastroesophageal disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid’s EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck® Esophageal Cell
Collection Device, is the first and only commercially available
diagnostic test capable of serving as a widespread screening tool
to prevent cancer and cancer deaths through early detection of
esophageal precancer in at-risk GERD patients. EsoGuard is
commercialized in the U.S. as a Laboratory Developed Test (LDT).
EsoCheck is commercialized in the U.S. as a 510(k)-cleared
esophageal cell collection device. EsoGuard, used with EsoCheck,
was granted FDA Breakthrough Device designation and is the subject
of two large, actively enrolling, international multicenter
clinical trials to support FDA PMA approval. Lucid is building a
network of Lucid Test Centers where at-risk GERD patients can
undergo the EsoCheck procedure for EsoGuard testing. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook, and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid’s management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid’s common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid’s clinical and preclinical studies; whether and
when Lucid’s products are cleared by regulatory authorities; market
acceptance of Lucid’s products once cleared and commercialized;
Lucid’s ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid has been monitoring
the COVID-19 pandemic and the pandemic’s impact on Lucid’s
businesses. Lucid expects the significance of the COVID-19
pandemic, including the extent of its effect on its financial and
operational results, to be dictated by, among other things, the
success of efforts to contain the pandemic and the impact of such
efforts on Lucid’s businesses. These factors are difficult or
impossible to predict accurately and many of them are beyond
Lucid’s control. In addition, new risks and uncertainties may arise
from time to time and are difficult to predict. For a further list
and description of these and other important risks and
uncertainties that may affect Lucid’s future operations, see
Lucid’s Registration Statement No. 333-259721 filed with the
Securities and Exchange Commission. Lucid disclaims any intention
or obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220307005536/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com
Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
過去 株価チャート
から 4 2024 まで 5 2024
PAVmed (NASDAQ:PAVMZ)
過去 株価チャート
から 5 2023 まで 5 2024